Literature DB >> 18216461

Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis.

Steven D Nathan1, Oksana A Shlobin, Shahzad Ahmad, Jim Koch, Scott D Barnett, Niv Ad, Nelson Burton, Kevin Leslie.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a disease with very high mortality.
OBJECTIVE: We sought to characterize serial changes in pulmonary artery pressures (PAP) in patients with advanced IPF who survive to transplant.
METHODS: Retrospective analysis of IPF patients comparing mean PAP at the time of initial evaluation for transplan- tation (mPAP(baseline)) with mPAP at the time of transplant (mPAP(follow-up)). The measurements were correlated with New York Heart Association (NYHA) functional class and oxygen requirements.
RESULTS: The final cohort consisted of 44 patients with serial right heart catheterization data. The mean mPAP(baseline) and mPAP(follow-up) were 22.5 and 32.7 mm Hg, respectively. 38.6% (17/44) of the patients had pulmonary hypertension (PH) at baseline. The majority of the non-PH patients developed PH during the serial time interval with a subsequent incidence of 77.8%. At the time of transplant, 86.4% of the patients had PH. There was a significant association between transplant NYHA class, severity of PH and oxygen requirements. Transplant NYHA class IV patients had a higher rate of mPAP change. The severity of PH at the time of transplant did not affect transplant outcomes.
CONCLUSION: PH is common and progressive in patients with advanced IPF who are transplant candidates. Serial change and severity of PAP elevations have a significant association with oxygen requirements and functional status, but not transplant outcomes. Whether or not progressive PH has a significant impact on outcomes without transplantation requires further study. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2008        PMID: 18216461     DOI: 10.1159/000114246

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  39 in total

1.  Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

Authors:  Rajeev Saggar; Dinesh Khanna; Daniel E Furst; Shelley Shapiro; Paul Maranian; John A Belperio; Neeraj Chauhan; Philip Clements; Alan Gorn; S Sam Weigt; David Ross; Joseph P Lynch; Rajan Saggar
Journal:  Arthritis Rheum       Date:  2010-12

Review 2.  Classification and diagnosis of pulmonary hypertension.

Authors:  Hector R Cajigas; Rana Awdish
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

3.  Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report.

Authors:  Jason M Elinoff; Richa Agarwal; Christopher F Barnett; Raymond L Benza; Michael J Cuttica; Ahmed M Gharib; Michael P Gray; Paul M Hassoun; Anna R Hemnes; Marc Humbert; Todd M Kolb; Tim Lahm; Jane A Leopold; Stephen C Mathai; Vallerie V McLaughlin; Ioana R Preston; Erika B Rosenzweig; Oksana A Shlobin; Virginia D Steen; Roham T Zamanian; Michael A Solomon
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

4.  Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters.

Authors:  D Papakosta; G Pitsiou; Z Daniil; M Dimadi; E Stagaki; A Rapti; K Antoniou; A Tzouvelekis; T Kontakiotis; S Tryfon; V Polychronopoulos; D Bouros
Journal:  Lung       Date:  2011-06-11       Impact factor: 2.584

Review 5.  Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies.

Authors:  Maya M Juarez; Andrew L Chan; Andrew G Norris; Brian M Morrissey; Timothy E Albertson
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

Review 6.  Pulmonary hypertension associated with lung diseases and hypoxemia.

Authors:  Michael J Cuttica
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

Review 7.  Epidemiology and management of common pulmonary diseases in older persons.

Authors:  Kathleen M Akgün; Kristina Crothers; Margaret Pisani
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-02-15       Impact factor: 6.053

Review 8.  Management of Pulmonary Hypertension in Patients with Chronic Lung Disease.

Authors:  Joan Albert Barberà; Isabel Blanco
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

9.  Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis.

Authors:  Laith Alkukhun; Xiao-Feng Wang; Mostafa K Ahmed; Manfred Baumgartner; Marie M Budev; Raed A Dweik; Adriano R Tonelli
Journal:  Respir Med       Date:  2016-06-02       Impact factor: 3.415

10.  Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension.

Authors:  Andrew J Bryant; Ryan P Carrick; Melinda E McConaha; Brittany R Jones; Sheila D Shay; Christy S Moore; Thomas R Blackwell; Santhi Gladson; Niki L Penner; Ankita Burman; Harikrishna Tanjore; Anna R Hemnes; Ayub K Karwandyar; Vasiliy V Polosukhin; Megha A Talati; Hui-Jia Dong; Linda A Gleaves; Erica J Carrier; Christa Gaskill; Edward W Scott; Susan M Majka; Joshua P Fessel; Volker H Haase; James D West; Timothy S Blackwell; William E Lawson
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-12-04       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.